The target 2-amino-[1,3,5]triazino[1,2-a]benzimidazoles (2-6) were synthesized via 5+1 heterocyclization of 2-guanidinobenzimidazole (1) using aldehydes, ketones or diethyl ethoxymethylenemalonate as the one-carbon cyclizing agents.
Introduction
Inhibitors of enzyme dihydrofolate reductase (DHFR) are known to be effective antibacterial, antiparasitic and antitumor agents [1] [2] [3] [4] . The investigations in this area have identified several chemical classes, including dihydros-triazines, to be promising in the development of new DHFR inhibitors [5] . However s-triazines fused with another heterocyclic ring have not been studied thoroughly. Only one compound, namely, 2-amino-4,4,7,8-tetramethyl-3,4-dihydro- [1, 3, 5] triazino[1,2-a]benzimidazole ( Figure 1 ) has been shown to possess inhibitory activity towards plasmodial DHFR [6, 7] . Using this compound as a prototype, we designed and synthesized several analogues without methyl groups at positions 7 and 8. It was investigated whether the substituents at position 4 as well as the conjugation in heterocyclic nucleus have an influence on DHFR inhibitory activity. At the same time we explored tautomeric preferences in the prepared compounds. 
Results and discussion
The target 2-amino- [1, 3, 5] triazino[1,2-a]benzimidazoles (2-6) were synthesized via 5+1 heterocyclization of 2-guanidinobenzimidazole (1) using aldehydes, ketones or diethyl ethoxymethylenemalonate as the one-carbon cyclizing agents.
Reactions of 2-guanidinobenzimidazole (1) with formaldehyde and benzaldehyde afforded 2-amino-3,4-dihydro- The prepared compounds (2-6) were fully characterized according to the analytical and spectroscopic properties (Tables 1-3) . Table 2) Compd. C-2 C-4 C-5a C-6 C-7 C-8 C-9 C-9a C-10 Group at C-4 according to a previously described method [8] . The compounds (2-6) for the DHFR inhibition bioassays were dissolved in DMSO. In order to ensure that the solvent per se did not have an effect on the enzymatic activity, negative control test was performed using DMSO at the same concentration. IC 50 was calculated for the active compounds.
The results of the biological assay are presented in Table 4 . Compound 4 with gem-dimethyl group at position 4 and structurally related to the prototype molecule was found to be most active. Compound 2 which does not have substituents at position 4 was more than 50 times less active than 4. Similar inhibition of DHFR was observed for the spiro compound 5. Compound 3 with phenyl ring at position 4 was not active.
Interestingly, compound 6, the fully conjugated analogue of 2, was twice more active. This is an indirect evidence that other forms either than 3,4-dihydro tautomeric form contributed to the inhibition of DHFR. 
Experimental
Melting points (uncorrected) were determined on a Gallenkamp melting point apparatus. IR spectra were performed on a Jasco FT-IR-430 spectrophotometer in KBr pellets. C NMR spectra were recorded on a
Bruker DPX-300 spectrometer, using DMSO-d 6 as a solvent and TMS as an internal reference. [1, 3, 5] triazino [1,2-a] 
2-Amino-3,4-dihydro

benzimidazole (2).
A solution of 1.75 g (10 mmol) 2-guanidinobenzimidazole (1) and 1.00 ml (10 mmol) 37% formaldehyde in dioxane (20 ml) was heated under reflux for 2 h. After cooling, the product was filtered, washed with ethanol, dried and recrystallized from DMF. [1, 3, 5] triazino [1,2-a] 
2-Amino-4-phenyl-3,4-dihydro
benzimidazole (3).
A solution of 1.75 g (10 mmol) 2-guanidinobenzimidazole (1), 1.00 ml (10 mmol) benzaldehyde and 0.50 ml piperidine in ethanol (20 ml) was heated under reflux for 3 h. After cooling, the product was filtered, washed with ethanol, dried and recrystallized from DMF-ethanol.
2-Amino-4,4-dimethyl-3,4-dihydro[1,3,5]triazino[1,2-a]benzimidazole (4).
A solution of 1.75 g (10 mmol) 2-guanidinobenzimidazole (1) and 0.50 ml piperidine in acetone (20 ml) was heated under reflux for 7 h. After cooling, the product was filtered, washed with acetone, dried and recrystallized from DMF-ethanol.
2'-Amino-3'H-spiro[cyclohexane-1,4'-[1,3,5]triazino[1,2-a]benzimidazole] (5).
A solution of 1.75 g (10 mmol) 2-guanidinobenzimidazole (1) and 1.55 ml (15 mmol) cyclohexanone in DMF (15 ml) was heated under reflux for 4 h. The reaction mixture was concentrated under vacuum. After cooling, the product was filtered, washed with ethanol, dried and recrystallized from DMF.
2-Amino-[1,3,5]triazino[1,2-a]benzimidazole (6).
A solution of 0.88 (5 mmol) 2-guanidinobenzimidazole (1) and 1.00 ml (5 mmol) diethyl ethoxymethylenemalonate in acetonitrile (20 ml) was heated under reflux for 5 h. After cooling, the product was filtered, washed with ethanol, dried and recrystallized from DMF.
